Is Masterworks the Robinhood of the Art Collecting World?


Image Credit: *lingling*, (Flickr)

A New Platform Lets You Buy Shares of Blue-Chip Paintings – But is Art a Wise Investment?

 

In the fall of 2018, a Banksy work, “Love is in the Bin,” sold for US$1.4 million.

Now the original buyer has put the work up for sale, and it’s expected to fetch over $5 million – that would amount to a return of more than 250% on the original investment.

What if, instead of the art market’s being the sole purview of the deep-pocketed, everyday people could buy shares of a pricy piece of art and sell the shares as they please?

That’s exactly what a new platform, Masterworks, seeks to do.

Art investment funds have existed for over a century. Masterworks, however, has put a new twist on an old practice in that the platform allows individuals to buy shares of specific artworks in $20 increments. Investors can then sell these shares in an easy-to-use secondary market or wait until Masterworks sells the piece and receive pro-rata proceeds.

 

This article was republished with permission from  The Conversation, a news site dedicated to sharing ideas from academic experts. It represents the research-based findings and thoughts of Kathryn Graddy Dean, Brandeis International Business School, and Fred and Rita Richman, Distinguished Professor in Economics, Brandeis University.

 

For nearly 10 years, I’ve taught a course on economics and the arts with art historian Nancy
Scott
. In this course, we spend time discussing the history and profitability of art investing, both in theory and in practice.

For those thinking of purchasing art purely for investment purposes, it’s important to understand how art investment funds have traditionally worked, and whether experts believe it’s a good investment.

The French Pool Their Resources

An early art investment fund was called The Skin of the Bear (La Peau de l’Ours), which was based in France during the beginning of the 20th century.

The name comes from a French fable that contains the aphorism “never sell the skin of the bear before you’ve actually killed it” – the French equivalent of “don’t count your chickens before they hatch” – and it alludes to the fact that investing in art can be a risky endeavor.

Partly intended as a means to support emerging post-impressionist artists, such as Picasso, Matisse and Gauguin, the fund was run as a syndicate in which a small number of partners each contributed identical amounts to purchase a collection of paintings. Businessman, art critic and collector Andre Level managed the fund and arranged the paintings’ sale. After the paintings were sold, he received 20% of the sale price for his work. The artists received 20% of the fund’s profits on top of the money they received from the original sale. The investors would then receive the rest in equal proportions.

This concept – returning a proportion of the sale price to the artist – is known as the droit de suite, or artist’s resale right. Versions of this are now law in most parts of the Western world other than the United States.

This first art fund was a success. It created demand for new artworks and supported innovative impressionist and modern artists, while providing a sizable return to its original investors.

Not All Funds are Equal

Another famous investment in art was made by the British Rail Pension Fund.

This fund was established in 1974 to manage a small proportion of the company’s employee retirement holdings, and the objective was to buy works of art over the course of 25 years before selling them off. The fund earned 11.3% in compound returns annually, but because of high inflation during much of that period, the actual gains were much lower.

Other notable art funds ended up as failures. Banque Nationale de Paris’ art fund sold its investment in 1999 at a loss and a fund run by British art dealer Taylor Jardine Ltd. did the same in 2003. Britain’s Department of Trade shut down The Barrington Fleming Art Fund in 2001 after determining it was set up under fraudulent circumstances. And Fernwood Art Investments, founded by former Merrill Lynch manager Bruce Taub, failed to even launch after Taub was found guilty of embezzling his investors’ funds in 2006.

Nonetheless, there are art funds that are still in operation, such as Anthea and The Fine Art Group, and, of course, banks and auction houses have long described investing in art as a suitable diversification strategy for the wealthy.

But what do economists say about art as an investment?

Is it Really a ‘Floating Crap
Game’?

Economic theory suggests that, by definition, investing in art could provide lower returns than investing in stocks. That’s because it’s thought of as a passion investment. Like investing in sports memorabilia, jewelry or coins, part of the return to investing in art ought to be the intrinsic enjoyment of the objects themselves. The total return consists of the monetary return and the enjoyment of ownership.

As stocks do not, for most people, provide this enjoyment value, the monetary returns to investing in these financial instruments should, in theory, be greater than the monetary returns to investing in art.

But it’s important to actually analyze the numbers.

One of the very first papers on the monetary return of art investing was published in 1986 and written by the late eminent economist William Baumol.

The title? “Unnatural Investment: Or Art as a Floating Crap Game.”

Baumol estimated the long-run inflation-adjusted returns to investing in art, over a 300-year period, to be just 0.6%. Some researchers have since estimated higher returns. For example, work by Yale finance professor Will Goetzmann and economists Jiangping Mei and Mike Moses found inflation-adjusted returns of 2% over 250 years and 4.9% over 125 years, respectively. Estimated returns vary based on the time period, sample and methodology.

Furthermore, these studies don’t include transaction fees, which, when it comes to art, can be sizable, thanks to the hefty commissions charged by the auction houses or private dealers for serving as the middlemen. They also don’t take into account sample selection; paintings that plummet in value often can’t be sold at auction.

Both the Goetzmann and the Mei and Moses studies, however, estimate that the performance of the stock market doesn’t seem to be correlated with returns on art investments. So there may be some benefit to investing in art as a way to diversify your portfolio.

Art for All?

Masterworks, however, is a bit different from the traditional art funds discussed above. Investors are buying shares of a single piece of art, rather than investing in a fund that includes multiple works. The price of entry is much lower, and, as long as there are willing buyers for the share of artwork, investors aren’t locked into the fund for a particular time period. Investors can earn a return just by selling shares that go up in value, without waiting for the artwork itself to be sold.

But like the traditional art funds, investors in shares of art sold by Masterworks will make money if the price of their artwork goes up, and lose their money if it goes down.

Ultimately, Masterworks seems innovative and fun. The format will likely appeal to a younger generation of investors, many of whom may have started investing small amounts through apps such as Robinhood ($HOOD).

The site is easy to navigate and could provide some enjoyment – even I was tempted to dabble in buying some shares.

But should you hope to get rich from investing in art? Probably not.

Furthermore, unlike Skin of the Bear, it doesn’t necessarily benefit emerging artists. Masterworks focuses on established works with a track record, by artists such as Banksy, Andy Warhol and Claude Monet, to name a few.

That being said, Masterworks could bring investing in art to a mass audience. But, caveat emptor: Art is a risky investment.

 

Suggested Reading:



AMC Theaters Now Accepts 4 Cryptocurrencies



Is it Proper to Yell “Market Crash” on a Crowded Message Board?





Making Sense of Non-Fungible Tokens



NFT Collectible Marketplace for DRAFTKINGS

 

Stay up to date. Follow us:

 

Cathie Wood Clears Way to Invest in Bitcoin ETFs from Canada


Canadian Bitcoin ETFs May Be Cathie Wood’s Solution

 

For every problem, there is a solution, and it looks like Cathie Wood may have finally found her answer. Here’s the problem. Wood, who is the founder of ARK Invest and the high-profile Chief Investment Officer of the company that has as its tagline: We Invest Solely In Disruptive
Innovation
 would like to more readily be able to gain exposure to Bitcoin through ETFs. The problem is, the U.S. Securities and Exchange Commission has not approved Cryptocurrency ETFs, so there are none in existence among the investment companies overseen by the SEC.

 

ARK BTC.X History

Over the past eight years, the SEC has rejected or delayed more than a dozen Bitcoin Exchange Traded Fund applications. The reasons given are concerns over sharp volatilities and potential risks of market manipulation. Back in June of this year, along with the company Swiss-based 21Shares, ARK Invest filed to create a Bitcoin ETF of their own to be called ARK 21Shares Bitcoin ETF. The joint filing is one of the delayed decisions.

The SEC has been dragging its feet on any Cryptocurrency ETFs and has not approved any. SEC Chair Gary Gensler says they’re studying all the ramifications and how the underlying coins or futures contracts may provide higher and lower levels of investor protection. Nothing sounds imminent in terms of a decision by the SEC, and it doesn’t even sound certain that there will be an ETF approved that invests directly in Bitcoin or other cryptocurrencies.

One of Wood’s funds, The ARK Next Generation Internet ETF,  already holds a significant amount of Bitcoin through a closed-end Grayscale Bitcoin Trust (GBTC). This trust owns coins that are held at a third-party custodian. The Grayscale Trust doesn’t track Bitcoin’s exchange rate tick-for-tick. Initially, the Grayscale Trust, which currently has $30 billion in assets, outperformed actual bitcoin and traded at as much as a 20% premium. This is because it became the preferred alternative as an asset that can be held more easily in many investment accounts, such as the ARK Next Generation Internet ETF. 

Wood’s ETF currently has 5.5% of its assets——worth about $314 million——in the Grayscale fund, which is its second-largest holding only behind Tesla (TSLA).

 

Current
Solution

Canada and Europe both moved ahead, allowing fund managers to offer Bitcoin and Ethereum in an ETF wrapper. In February, Grayscale began underperforming Bitcoin and underperforming the first Canadian Bitcoin ETF.

 

 

Wood’s asset-management company, ARK Invest, revised the prospectus of the $5.7 billion ARK Next Generation Internet ETF so the fund can hold cryptocurrencies via Canadian ETFs. Given all the uncertainties, it might be wise to diversify crypto holdings through the Canadian ETFs. Others have made similar moves. Recently, the $1.3 billion Amplify Transformational Data Sharing ETF (BLOK), which is actively managed and mainly invests in blockchain-related businesses, also bought shares in three Canadian Bitcoin ETFs.

Take-Away

The diversification Bitcoin offers relative to other “disruptive innovations” is high. The volatility also presents a unique opportunity. As U.S. fund managers like those at ARK Invest seek to provide an above-average return for their investors, they will find workarounds to gain the exposure they believe is best. These workarounds are at times more costly than a direct holding or one that is domestic.

In the case of ETFs, the ease with which they can be bought and sold and if ever approved in the U.S., used in fund management or qualified retirement accounts, may cause them to trade at a premium to the assets they hold. We won’t know this for sure if the SEC continues to hold off on making a decision.

 

Suggested Reading:



Will the SEC Allow ETFs to Own Cryptocurrency?



Coinbase Receives an Enforcement Letter from the SEC





What’s in the Surprise Cryptocurrency Bill



Elon Musk, Jack Dorsey, and Cathie Wood Drop Bombshells at Bitcoin Conference

 

Sources:

https://www.sec.gov/Archives/edgar/data/0001869699/000119312521201955/d165184ds1.htm

https://www.bloomberg.com/news/articles/2021-09-13/cathie-wood-s-ark-grants-itself-power-to-buy-canada-bitcoin-etfs

https://www.barrons.com/articles/cathie-woods-ark-invest-eyes-canadian-crypto-etfs-51631569128?mod=hp_LEAD_1_B_1

 

Stay up to date. Follow us:

 

Release – CoreCivic Provides Update on U.S. Marshals Service Contract for the West Tennessee Detention Facility


CoreCivic Provides Update on U.S. Marshals Service Contract for the West Tennessee Detention Facility

 

BRENTWOOD, Tenn., Sept. 17, 2021 (GLOBE NEWSWIRE) — As has been previously disclosed, CoreCivic, Inc. (NYSE: CXW) (the Company) has a direct contract with the U.S. Marshals Service (USMS) at the 600-bed West Tennessee Detention Facility in Mason, Tennessee that is scheduled to expire on September 30, 2021. The Company recently was provided with a definitive inmate population ramp down plan from the USMS indicating that all inmates will be transferred out of the facility by September 30, 2021. As a result, the Company does not expect the USMS to exercise its renewal option under the existing contract.

The Company has been actively marketing the facility to other government agencies, and in August 2021, the Company submitted a formal response to a government agency’s request for proposal to utilize the West Tennessee Detention Facility. However, the Company can provide no assurances that it will be successful in entering into a new contract with the government agency.

The revenue generated from the USMS at the West Tennessee Detention Facility for the year ended December 31, 2020, and six months ended June 30, 2021, was $18.4 million and $10.2 million, respectively. For the year ended December 31, 2020, the facility incurred a $1.4 million net operating loss, and for the six months ended June 30, 2021, the facility generated net operating income of $0.8 million.

About CoreCivic

CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that serve the public good through corrections and detention management, a network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believes it is the largest private owner of real estate used by government agencies in the U.S. CoreCivic has been a flexible and dependable partner for government for more than 35 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good.

Forward-Looking Statements

This press release contains statements as to our beliefs and expectations of the outcome of future events that are “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These include, but are not limited to, the risks and uncertainties associated with: (i) changes in government policy (including the United States Department of Justice, or DOJ, not renewing contracts as a result of President Biden’s Executive Order on Reforming Our Incarceration System to Eliminate the Use of Privately Operated Criminal Detention Facilities) (two agencies of the DOJ, the United States Federal Bureau of Prisons and the United States Marshals Service, utilize our services), legislation and regulations that affect utilization of the private sector for corrections, detention, and residential reentry services, in general, or our business, in particular, including, but not limited to, the continued utilization of our correctional and detention facilities by the federal government, and the impact of any changes to immigration reform and sentencing laws (we do not, under longstanding policy, lobby for or against policies or legislation that would determine the basis for, or duration of, an individual’s incarceration or detention); (ii) our ability to obtain and maintain correctional, detention, and residential reentry facility management contracts because of reasons including, but not limited to, sufficient governmental appropriations, contract compliance, negative publicity and effects of inmate disturbances; (iii) changes in the privatization of the corrections and detention industry, the acceptance of our services, the timing of the opening of new facilities and the commencement of new management contracts (including the extent and pace at which new contracts are utilized), as well as our ability to utilize available beds; (iv) general economic and market conditions, including, but not limited to, the impact governmental budgets can have on our contract renewals and renegotiations, per diem rates, and occupancy; (v) fluctuations in our operating results because of, among other things, changes in occupancy levels, competition, contract renegotiations or terminations, increases in costs of operations, fluctuations in interest rates and risks of operations; (vi) the duration of the federal government’s denial of entry at the United States southern border to asylum-seekers and anyone crossing the southern border without proper documentation or authority in an effort to contain the spread of COVID-19; (vii) government and staff responses to staff or residents testing positive for COVID-19 within public and private correctional, detention and reentry facilities, including the facilities we operate; (viii) restrictions associated with COVID-19 that disrupt the criminal justice system, along with government policies on prosecutions and newly ordered legal restrictions that affect the number of people placed in correctional, detention, and reentry facilities, including those associated with a resurgence of COVID-19; (ix) whether revoking our real estate investment trust, or REIT, election, effective January 1, 2021, and our revised capital allocation strategy can be implemented in a cost effective manner that provides the expected benefits, including facilitating our planned debt reduction initiative and planned return of capital to shareholders; (x) our ability to successfully identify and consummate future development and acquisition opportunities and our ability to successfully integrate the operations of our completed acquisitions and realize projected returns resulting therefrom; (xi) our ability, following our revocation of our REIT election, to identify and initiate service opportunities that were unavailable under the REIT structure; (xii) our ability to have met and maintained qualification for taxation as a REIT for the years we elected REIT status; and (xiii) the availability of debt and equity financing on terms that are favorable to us, or at all. Other factors that could cause operating and financial results to differ are described in the filings we make from time to time with the Securities and Exchange Commission.

CoreCivic takes no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services.

Contact:    Investors: Cameron Hopewell – Managing Director, Investor Relations – (615) 263-3024
Media: Steve Owen – Vice President, Communications – (615) 263-3107

Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC


Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC

 

– Posters presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

– Preliminary data showed meaningful clinical activity of AL101 6mg monotherapy with 70% disease control rate

– AL101 was well tolerated with manageable side effects

REHOVOT, Israel and WILMINGTON, Del., Sept. 16, 2021 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced new preliminary clinical data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations. The data is being presented at the 2021 ESMO Virtual Congress as an ePoster. In a separate ePoster presentation, Ayala presented new preclinical results evaluating the potential of AL101 in combination with approved cancer therapies for dual targeting of ACC tumours.

“ACC is an orphan disease with no approved therapies and patients with Notch mutations have a more aggressive disease course and poorer survival outcomes as compared to patients with Notch wild-type. R/M ACC remains a significant area of unmet need, and I am encouraged by the preliminary results that AL101 monotherapy has demonstrated to-date. Coupled with new preclinical data showing that AL101 in combination with approved targeted therapies could potentially treat a greater proportion of ACC tumors, regardless of Notch mutations, it will be exciting to see how AL101 may be developed as a viable treatment option for R/M ACC patients,” said Alan L. Ho, M.D., Ph.D., Medical Oncology, Memorial Sloan Kettering Cancer Center and Lead Investigator in The ACCURACY Trial. “While these results are still preliminary, the safety profile of AL101 and the disease control rate of 70% are promising indicators in this incredibly difficult to treat patient population.”  

“The preliminary safety and efficacy data from the 6mg cohort of our ongoing ACCURACY trial of AL101 highlights a favourable profile. We are pleased to see that AL101’s safety profile continues to be tolerable and manageable, providing us with potential dosing flexibility as we continue to advance our development plans,” said Gary Gordon, M.D., Ph.D., Chief Medical Officer of Ayala. “We continue to see strong potential for AL101 to transform the treatment landscape for R/M ACC patients with Notch mutations and we look forward to reporting additional clinical data in 2022.”

Preliminary Safety and Efficacy Data from 6mg Cohort of ACCURACY Phase 2 Trial:
Ayala presented new preliminary 6mg data from its ongoing ACCURACY Phase 2 clinical trial evaluating the safety and efficacy of AL101 monotherapy for the treatment of patients with R/M ACC harboring Notch-activating mutations. The Phase 2 ACCURACY clinical trial is an open-label, single-arm, multi-center study to assess the clinical activity of AL101 using radiographic assessments of patients with R/M ACC demonstrating disease progression within 6 months prior to dosing.

As of July 9, 2021, all 42 patients enrolled in the 6mg cohort were treated and evaluable for safety and 33 were evaluable for efficacy.

Efficacy:
All evaluable patients were assessed for efficacy for a best response by investigators using RECIST 1.1 criteria.

  • Disease control rate (DCR) (defined as partial response and stable disease) was 70% (23/33 patients).
  • Partial responses (PR) were observed in 3 patients (9%).
  • Stable disease (SD) was observed in 20 patients (61%).
  • Progressive disease (PD) was observed in 8 patients (24%).
  • Two patients were determined to be evaluable per protocol but their scans were not available for analyses.
  • Study is ongoing with several patients remaining on drug as of the cutoff date.

Safety:
AL101 6mg QW treatment in patients with R/M ACC was well tolerated with manageable side effects consistent with those observed in the 4mg QW cohort with no new adverse events (AEs) specific to the 6mg cohort.

  • Most common treatment-related (TR) AEs of any grade were diarrhea (76%), fatigue (48%), nausea (41%), hypophosphatemia (29%), vomiting (26%) and decreased appetite (26%).
  • Treatment-related diarrhea was common and occurred in 32 patients (76%) and most were grades 1 and 2. Treatment-related serious diarrhea occurred in 6 patients (14%).
  • Serious TRAEs were reported in 31% of patients with treatment-emergent AEs leading to discontinuation in 26% of patients.
  • Two patients experienced a grade 4 TRAE: one patient experienced a seizure and one patient experienced drug-induced liver injury.
  • Four treatment-emergent patient deaths occurred (10%), one of which was assessed by the investigator to be treatment related.

Ayala plans to report additional data from the ACCURACY study in 2022.

“Our new preclinical study evaluating the potential of improved efficacy of AL101 in combination with approved targeted therapies represents a promising potential approach for additive or synergistic activity of gamma secretase inhibition when combined with various mechanisms of action,” said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. “We observed stronger tumor growth inhibition in ACC PDX models with Notch pathway genes downregulated regardless of mutational status in the combination arm of the study, as compared to AL101 monotherapy. Based on these results, we believe there is a strong rationale for a combination therapy approach to treating ACC, in addition to other cancer indications in which Notch is dysregulated. We look forward to the further development of AL101 in Notch dysregulated tumors, both as monotherapy and in combination.”

Preclinical Results of AL101 Combined with Other Drugs for Dual Targeting of Notch Dysregulated Tumors:
In this preclinical study evaluating the potential of combination therapy of AL101 in PDX models of ACC, Ayala compared the differential gene expression of ACC tumors versus normal matched tissue regardless of Notch activation status. Combination compounds were selected based on determination of the pathways that are implicated with approved oncology therapies, including inhibitors of Bcl2, HDAC, FGFR & CDK4/6. Based on a comparison of AL101 alone, each approved drug alone, and the combination of each drug with AL101, Ayala observed additive or synergistic activity of AL101 combined with agents of various mechanisms of action. AL101 in combination demonstrated significant tumor growth inhibition, including regressions, compared to each drug alone, showing significant benefit with dual targeting of Notch and other dysregulated pathways. Additionally, the study indicated that crosstalk between signaling pathways may increase the efficacy of AL101 in R/M ACC regardless of Notch mutational status. These preclinical results demonstrated a compelling rationale for potential expansion to a larger portion of ACC patients and to additional cancer indications.

About Adenoid Cystic Carcinoma (ACC)

ACC is a rare malignancy of the secretory glands including salivary glands, accounting for about 10% of all salivary gland tumors with an annual incidence of 3,400 in the U.S. There is currently no approved standard of care for patients with recurrent/metastatic ACC. Patients with locoregional disease undergo surgery and radiation therapy, with recurring disease treated by chemotherapy. ACC is an immunologically “cold” tumor that is refractory to chemotherapy, with a recurrence rate of about 60% after initial surgery. The Notch pathway has been determined to be an oncogenic driver of ACC and its dysregulation plays a key role in tumorigenesis and correlates with a distinct pattern of metastasis and a poor prognosis.

About AL101

AL101 is an investigational small molecule Gamma Secretase Inhibitor (GSI) that is designed to potently and selectively inhibit Notch 1, 2, 3 and 4, and is currently being evaluated in two Phase 2 clinical studies, ACCURACY and TENACITY, in patients with adenoid cystic carcinoma (ACC) and in patients with triple negative breast cancer (TNBC), respectively. AL101 is designed to inhibit the expression of Notch gene targets by blocking the final cleavage step by the gamma secretase required for Notch activation. Ayala obtained an exclusive, worldwide license to develop and commercialize AL101 from Bristol-Myers Squibb Company in November 2017. AL101 was granted U.S. FDA Fast Track Designation and Orphan Drug Designation for the treatment of ACC.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements relating to our development of AL101, including its treatment potential, the promise and potential impact of our preclinical or clinical trial data, and the timing of additional data from clinical trials of AL101. These forward-looking statements are based on management’s current expectations. The words “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our operations, including our preclinical studies and clinical trials, and the continuity of our business; we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our cash runway; our limited operating history and the prospects for our future viability; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in regulatory approval; our requirement to pay significant payments under product candidate licenses; the approach we are taking to discover and develop product candidates and whether it will lead to marketable products; the expense, time-consuming nature and uncertainty of clinical trials; enrollment and retention of patients; potential side effects of our product candidates; our ability to develop or to collaborate with others to develop appropriate diagnostic tests; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; risks associated with international operations; our ability to retain key personnel and to manage our growth; the potential volatility of our common stock; costs and resources of operating as a public company; unfavorable or no analyst research or reports; and securities class action litigation against us. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (SEC) on March 24, 2021 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

Neovasc Announces FDA Approval of COSIRA-II Clinical Trial


Neovasc Announces FDA Approval of COSIRA-II Clinical Trial

 

Company on Schedule to Commence Trial Late This Year

VANCOUVER and MINNEAPOLIS, Sept. 16, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received FDA approval for the Investigational Device Exemption (“IDE”) regarding the COSIRA-II IDE Clinical Trial. 

Following multiple discussions with FDA over the past several months, the approved protocol for the COSIRA-II study is designed to answer key questions arising from the October 2020 Circulatory Systems Devices Panel Meeting regarding the Neovasc Reducer™ (“Reducer”). The approval of the supplement is consistent with Neovasc’s internal target, and the Company remains on track to enroll the first patient in the trial late this year.

COSIRA-II is a randomized, sham-controlled trial investigating the safety and effectiveness of the Reducer for patients suffering from refractory angina. The primary endpoint of the trial is change in exercise tolerance testing time via a modified Bruce protocol between baseline and six-month follow-up. The study is planned to enroll approximately 380 patients at up to 50 sites in the United States and will also include limited sites outside of the United States. The trial will include patients with Canadian Cardiovascular Society Class III-IV refractory angina on maximally tolerated medical therapy without further options for revascularization via coronary intervention or bypass grafting. The principal investigators of the trial are Gregg Stone, M.D., Mt. Sinai Health System, New York, NY and Tim Henry, M.D., Christ Hospital, Cincinnati, OH.

“FDA approval of the IDE Supplement is another important milestone for Neovasc,” commented Lisa Becker, Vice President of Regulatory Affairs, Global Angina Therapies, at Neovasc. “We are grateful for the collaborative work with FDA and we are pleased that our study initiation remains on track.” She continued, “Refractory angina is a debilitating condition, and we are excited to offer patients in the US and Canada a clinical trial with a treatment option that may alleviate their suffering.”

About Reducer  

The Reducer is CE-marked in the European Union and Under Investigation in the United States for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow within the myocardium of the heart and increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary stent and can be completed in approximately 20 minutes.  

While the Reducer is not approved for commercial use in the United States, the FDA granted Breakthrough Device designation to the Reducer in October 2018.

Refractory angina, resulting in continued symptoms despite maximal medical therapy and without revascularization options, is estimated to affect 600,000 to 1.8 million Americans, with 50,000 to 100,000 new cases per year. 

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel, and Europe. For more information, visit: www.neovasc.com.

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to,the COSIRA-II study’s ability to answer key questions arising from the October 2020 Circulatory Systems Devices Panel Meeting,the Company remaining on track with respect to the enrolling of patients, the planned details of the COSIRA-II study and the expected timing thereof and the growing cardiovascular marketplace. Many factors and assumptions could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the doubt about the Company’s ability to continue as a going concern; risks related to the recent COVID-19 coronavirus outbreak or other health epidemics, which could significantly impact the Company’s operations, sales or ability to raise capital or enroll patients in clinical trials and complete certain Tiara development milestones on the Company’s expected schedule; risks relating to the Company’s need for significant additional future capital and the Company’s ability to raise additional funding; risks relating to the sale of a significant number of Common Shares; risks relating to the possibility that the Company’s common shares (the “Common Shares”) may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company’s conclusion that it did have effective internal control over financial reporting as of December 31, 2020 but not at December 31, 2019 and 2018; risks relating to the Common Share price being volatile; risks relating to the possibility that the Common Shares may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company’s significant indebtedness, and its effect on the Company’s financial condition; risks relating to lawsuits that the Company is subject to, which could divert the Company’s resources and result in the payment of significant damages and other remedies; risks relating to claims by third-parties alleging infringement of their intellectual property rights; risks relating to the Company’s ability to establish, maintain and defend intellectual property rights in the Company’s products; risks relating to results from clinical trials of the Company’s products, which may be unfavorable or perceived as unfavorable; the Company’s history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company’s products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more competitors may develop more effective or more affordable products; risks relating to the Company’s ability to achieve or maintain expected levels of market acceptance for the Company’s products, as well as the Company’s ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; risks relating to the Company’s ability to convince public payors and hospitals to include the Company’s products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks relating to the extensive regulation of the Company’s products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks relating to post-market regulation of the Company’s products; risks relating to health and safety concerns associated with the Company’s products and industry; risks relating to the Company’s manufacturing operations, including the regulation of the Company’s manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risks relating to the possibility of animal disease associated with the use of the Company’s products; risks relating to the manufacturing capacity of third-party manufacturers for the Company’s products, including risks of supply interruptions impacting the Company’s ability to manufacture its own products; risks relating to the Company’s dependence on limited products for substantially all of the Company’s current revenues; risks relating to the Company’s exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to the possibility that the Company could be treated as a “passive foreign investment company”; risks relating to breaches of anti-bribery laws by the Company’s employees or agents; risks relating to future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company’s dependence upon key personnel to achieve its business objectives; risks relating to the Company’s ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company’s management systems and resources in periods of significant growth; risks relating to consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company’s ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to conflicts of interests among the Company’s officers and directors as a result of their involvement with other issuers; and risks relating to anti-takeover provisions in the Company’s constating documents which could discourage a third-party from making a takeover bid beneficial to the Company’s shareholders. These risk factors and others relating to the Company are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Information Form and in the Management’s Discussion and Analysis for the three and six months ended June 30, 2021 (copies of which may be obtained at www.sedar.comor www.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.

Investors

Mike Cavanaugh

Westwicke/ICR

Phone: +1.646.877.9641

Mike.Cavanaugh@westwicke.com

Media

Sean Leous

Westwicke/ICR

Phone: +1.646.866.4012

Sean.Leous@westwicke.com

Edge Computing Can Take AI Out of the Cloud and to the Moon


Image Credit: Inspiration4 Photos (Flickr)

The Most Effective Artificial Intelligence Will Never Exist in the Cloud

 

As SpaceX sends amateur astronauts into orbit and a related company struggles to get its EVs autopilot perfect, we can understand the increased need for edge computing. Or, as some would call edge, “AI on the fly,” the challenge of bringing artificial intelligence as close to the need for output or intervention as possible. The reality of AI computing is, the speed of WiFi, radio waves, and even light are not instant; bringing the decision-making computer as close to the outcome as possible allows for more successful outcomes.

Artificial intelligence (AI) applications include language processing, military decision making, robotic control, face recognition, aviation, hands-free driving, and a long list including much that has not yet been thought of. Many of the mentioned applications are now confined to data centers with a geographic address and significant storage. For many applications, AI decisions are best if onsite or at the “edge” close to the user situation that benefits from the support. Communication out to a network would slow down the response. This is what edge computing provides, onsite decisions with minimal delay in live situations.

Breaking the Climate Controlled Ceiling

Bringing AI closer to the situation with systems that are transportable and durable enough to survive the elements outside of a controlled environment is critical to AI advances. The technological considerations are massive, they include computational ability, durability, heat survival, dampness, size, weight, and power consumption.

A company meeting this challenge is One Stop Systems (OSS). They’ve developed high-end GPU-level processing with massive solid-state storage and minimal network delay. One of the “onboard” challenges being met by their products includes making computations using the surge in information from new sensors and data capture technology. These lead to even more raw information and a growing number of situations with inputs that must be resolved quickly. In real-life situations, there is no time for complex combinations of data to be sent to the Cloud to help with an imminent situation like a vehicle collision or a sudden combat event. Simply, edge computing technology is the future of AI technology – without it, the effectiveness of AI stalls at some point.

 

Virtual Road Show Series – Thursday, September 16 @ 1pm EDT

Join One Stop Systems CEO David Raun and CFO John Morrison for this exclusive corporate presentation, followed by a Q & A session moderated by Joe Gomes, Noble’s senior research analyst, featuring questions taken from the audience. Registration is free and open to all investors, at any level.

Registration is fast and free.  |  View All Upcoming Road Shows

 

Growth Trend of Edge Computing

In 2018, only 10% of generated data was created and processed on board or at the edge. By 2025, it is expected to grow to 75%. Processing simply must be on location to meet the growing needs. Transporting information to an outside server environment unnecessarily could be considered reckless. Transportable AI that has the computational bandwidth and strength is the future of non-human decision-making. Beyond environmental durability, upcoming systems would also have to provide cybersecurity at a level that isn’t possible with Cloud or server solutions (meet FIPS 140-2).

Take-Away

The guts of a machine that takes four amateur astronauts into space, or the onboard computer in a car that avoids an accident after the driver falls to sleep will be the unsung heroes in our amazing technological strides forward.  The companies behind the scenes, building out edge and other technologies that make these achievements possible are experiencing increased demand. Investors would be wise to pay attention to these underlying technologies and the providers.

At 1 pm ET today (Sept. 16)  One Stop Systems (OSS) will be live with a virtual roadshow available only through Channelchek. There is no cost to attend virtually and listen to the management presentation and submit questions. Edge computing is a very interesting and growing field; learn more by attending the virtual
event.

 

Suggested Reading:



Edge Computing Importance to AI Applications



Trading Technology Continues To Level the Playing Field





This is What Could Slam the Brakes on EV Growth



The SpaceX Inspiration4 Will Bring Space Tourism Closer to Reality

 

Sources:

https://www.wolfssl.com/license/fips/?gclid=Cj0KCQjw1ouKBhC5ARIsAHXNMI9M0RmWkamdiEsaGUqbm4x_KnqJZPdgpaSyWjD3GiDG1YIz_fJKTVMaAiBhEALw_wcB

https://onestopsystems.com/blogs/whitepapers/transportable-ai-brings-high-performance-high-bandwidth-decision-making-to-the-edge

 

Stay up to date. Follow us:

 

AMC Theaters Now Accepts 4 Cryptocurrencies


Tickets and Concessions Using Your Cryptocurrency Wallet at AMC Theaters

 

AMC Movies is being cheered and booed by cryptocurrency patrons as it allows three more digital currencies to be used to purchase tickets and popcorn. Interestingly one of the more popular currencies is still not among the four accepted at the movie chain. Bitcoin had already been accepted by the theater chain, taking three others is a nod to the credibility and usability of alternate currencies. However, as of August 2021, there are 5840 cryptocurrencies; choosing four, leaves out many large and small coins.

 

What Occurred

Movie-theater chain AMC Entertainment Holdings ($AMC) has been accepting Bitcoin (BTC.X) for purchases at its theaters.  They’ve announced a move to accept three other types of digital currencies for patrons making online ticket and concession purchases during 2021.

 

Source: Twitter

 

The company’s CEO, Adam Aron announced this in a Twitter post addressed to “cryptocurrency enthusiasts” late Wednesday (September 15). He tweeted that Ethereum (ETH.X), Litecoin (LTC.X), and Bitcoin Cash (a derivative of the digital currency they already accept) would be acceptable in addition to Bitcoin. However, Dogecoin (DOGE.X), the most exchanged coin on Robinhood, is not part of the four coins accepted. There has been no public word as to why AMC has a no Doge’s allowed rule.

Aron had previously announced that AMC would accept Bitcoin for payments back in August during the company’s most recent quarterly earnings call.

 

What it Means for
Crypto

It is the latest company to join the wider acceptance of digital currencies. Fintech firms PayPal (PYPL) and Square (SQ) allowed users to exchange and even store Bitcoin as well as transact with it. PayPal users can also do the same with Ethereum, Litecoin, and Bitcoin Cash (BCH.X). Twitter followers of Elon Musk know Tesla (TSLA) began accepting Bitcoin for payments earlier this year. Elon Musk later tempered his talk with concerns around crypto mining’s environmental impact (not value).

AMC’s move does represent another step by a recognized brand toward wider acceptance of the larger cryptocurrencies. This can be thought of as bullish for the entire industry.

Take-Away

Bitcoin and other cryptocurrencies were mocked just a few years ago as not a serious idea. AMC and those that were buying the stock were ridiculed last year during the coronavirus lockdown that prevented theaters from operating. This week, AMC is providing a nod to cryptocurrencies and the entire industry. Although highly popular Dogecoin was not also part of AMC’s initial four, cryptocurrency believers can still feel confident that this is a big vote in favor of their convictions.

 

Suggested Reading:



The Coinbase Nasdaq Listing Offers a Crypto Diversifier



Can Wall Street Giants Put Crypto on the Menu?





Decentralized Finance, is it the Future?



Michael Burry vs Cathie Wood is Not a Fair Competition

 

Sources:

https://www.barrons.com/articles/amc-cryptos-bitcoin-51631794500?mod=hp_LEADSUPP_1

https://twitter.com/CEOAdam/status/1438298684266098688/photo/1

https://investor.amctheatres.com/corporate-overview/?_ga=2.36302503.608719830.1631809592-667952136.1631809592

 

Stay up to date. Follow us:

 

Pro Football Retired Players Association Announces Partnership with Esports Entertainment Group for Its Gridiron Gaming Initiative

 


Pro Football Retired Players Association Announces Partnership with Esports Entertainment Group for Its Gridiron Gaming Initiative

 

Newark, New Jersey and Arlington, Virginia–(Newsfile Corp. – September 16, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (NASDAQ: GMBLW) (or the “Company”) has signed a partnership agreement with the Pro Football Retired Players Association (PFRPA), a national membership organization that develops benefits and programs for retired NFL players, to be its official esports partner and tournament platform provider. The partnership will broaden the reach of PFRPA’s Gridiron Gaming initiative through a multi-tiered program, focused on expanding retired NFL players’ presence in esports, while producing unique fan engagement experiences. The comprehensive program will include learning opportunities, live-streamed content and virtual and in-person tournaments.

“Esports Entertainment Group brings a wealth of knowledge, innovation and expertise, all important factors in our decision to develop this strategic partnership for Gridiron Gaming,” said PFRPA Senior Director Joe Agbasi. “When we started this esports program, we set out to create engaging tournaments for our retired NFL players, esports athletes, gaming enthusiasts and fans. By teaming up with EEG, we can follow through on those aspirations while developing fun, exciting content. We’re proud to partner to offer interactive, family-friendly experiences for patrons interested in gaming and esports.”

Virtual tournaments will be operated through the Company’s Esports Gaming League platform, and in-person events will be held at Helix eSports facilities.

“We’re really excited to come together with the PFRPA and help bring a truly unique experience to their community,” said Magnus Leppäniemi, President of Esports at Esports Entertainment Group. “The partnership includes a great opportunity for players to engage their fan base through a variety of esports activities including in person events and streaming.”

The Company’s esports tournament platform enables live and online events and tournaments where gamers can compete and enjoy a wide range of content relating to esports and video games on a proprietary technology platform. Services include full turnkey esports events, live broadcast production, game launches and online branded tournaments.

“Esports has grown and keeps growing in popularity over the years, so I’m so glad we’re in the game,” said Jack Youngblood, NFL Hall of Famer and PFRPA Board Member. “To have the opportunity to team up with a premier partner that understands how to bring together different generations, while having fans of new and traditional sports meet in the same arena, is something special.”

Gridiron Gaming is PFRPA’s esports initiative that provides retired players an opportunity to compete again, while offering fans a chance to engage with their NFL heroes. Gridiron Gaming launched in 2019 and has since produced several esports tournaments.

About Pro Football Retired Players Association (PFRPA)

PFRPA is a champion for retired NFL players, dedicated to bettering the lives of those who contributed to the game. PFRPA, the first court-established retired NFL player organization, through its leadership and dedication, has been on a mission to solidify and preserve the legacy of retired NFL players. Through the Greater Good Fund, PFRPA’s 501(c)(3) charitable foundation, PFRPA develops various health and welfare programs, designed exclusively for retired NFL players. The Football Greats Alliance, PFRPA’s licensing agency, develops partnerships to drive meaningful revenue for retired NFL players and provide revenue for the Greater Good Fund to support all retired players. To date, more than 10,000 retired players and more than 2,500 players’ spouses have enrolled in PFRPA insurance benefits. For more information about PFRPA, visit www.pfrpa.com.

About Esports Entertainment Group

Esports Entertainment Group is a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Our mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports. From traditional sports partnerships with professional NFL/NHL/NBA/FIFA teams, community-focused tournaments in a wide range of esports, and boots-on-the-ground LAN cafes, EEG has influence over the full-spectrum of esports and gaming at all levels. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:
U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498

dave@redchip.com

Media Inquiries
brandon.apter@esportsentertainmentgroup.com

Investor Relations Inquiries
Jeff@esportsentertainmentgroup.com

QuickChek – September 16, 2021



Neovasc Announces FDA Approval of COSIRA-II Clinical Trial

Neovasc announced that it has received FDA approval for the Investigational Device Exemption (“IDE”) regarding the COSIRA-II IDE Clinical Trial

Research, News & Market Data on Neovasc



Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial

Ayala Pharmaceuticals announced new preliminary clinical data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial

Research, News & Market Data on Ayala Pharmaceuticals

Watch recent presentation from Ayala Pharmaceuticals



Pro Football Retired Players Association Announces Partnership with Esports Entertainment Group for Its Gridiron Gaming Initiative

Esports Entertainment Group announced it has signed a partnership agreement with the Pro Football Retired Players Association

Research, News & Market Data on EEG

Watch recent presentation from EEG



Energy Fuels Establishes the San Juan County Clean Energy Foundation with Potential to Contribute Millions to Local Communities

Energy Fuels announced the establishment of the San Juan County Clean Energy Foundation, a fund specifically designed to contribute to the communities surrounding Energy Fuels’ White Mesa Mill in Southeastern, Utah

Energy Fuels Hosts Mining, Environmental and Political Heavyweights to Showcase Uranium Activities and Introduce Production of Rare Earths at its Blanding, Utah Facility

Energy Fuels announced the commencement of production and shipments of an intermediate rare earth element product, called mixed rare earth carbonate, at its Utah-based White Mesa Mill

Research, News & Market Data on Energy Fuels

Watch recent presentation from Energy Fuels

 

Stay up to date. Follow us:

 

Energy Fuels Hosts Mining, Environmental and Political Heavyweights to Showcase Uranium Activities and Introduce Production of Rare Earths at its Blanding, Utah Facility

 

 


Energy Fuels Hosts Mining, Environmental and Political Heavyweights to Showcase Uranium Activities and Introduce Production of Rare Earths at its Blanding, Utah Facility

 

Shipments of commercial quantities of rare earths from Energy Fuels’ White Mesa Mill in Blanding represent a milestone in the creation of a new supply chain reducing dependence on foreign suppliers, while boosting significant economic potential to the area

BLANDING, UtahSept. 16, 2021 /CNW/ – Energy Fuels’ President and CEO, Mark Chalmers is hosting business, community and industry heavyweights in Blanding, Utah to introduce the commencement of production and shipments of an intermediate rare earth element (“REE”) product, called mixed rare earth carbonate (“RE Carbonate”), at its Utah-based White Mesa Mill (the “Mill”). Approximately 15 containers of RE Carbonate (300 tonnes of product) produced at the Mill is being shipped to Europe where it will be processed into separated rare earth oxides and other value-added RE compounds, thereby creating a new U.S. to Europe RE supply chain along with new opportunities and financial benefits for the surrounding communities. The Mill will be producing rare earths as a complement to its established uranium production business.

The Company will also showcase its U.S. industry-leading uranium production capabilities. Energy Fuels has been the largest producer of uranium in the U.S. for the past several years, boasting more uranium production facilities, mines and capacity than any other U.S. company. The White Mesa Mill is the largest uranium production facility in the US and America’s only operating uranium mill. Uranium is seeing increased interest recently, as it is the fuel for nuclear energy, which is the largest source of clean, carbon free energy in the U.S.

REEs are necessary in the production of hundreds of everyday and specialty items with a wide range of consumer applications, including cell phones, computer hard drives, electric and hybrid vehicles, and flat screen monitors and televisions. They also have significant national defense uses including electronic displays, guidance systems, lasers, and radar and sonar systems. Furthermore, with the global push to reduce greenhouse gas emissions, the expansion of green technologies such as solar and wind will continue to play a critical role, and REEs are a fundamental raw material used in the manufacturing of these clean energy sources. There are currently no U.S. companies producing separated REE oxides or any other advanced or value-added REE compounds, thereby making the US 100% dependent on the importation of these critical materials. Energy Fuels is determined to reverse that reliance and lessen the risk of disruption to the clean energy economy and our national defense. 

“This is an exciting time for all of us at Energy Fuels in both the uranium and rare earth sectors,” said Chalmers. “We believe the San Juan County community will benefit greatly from this rare earth initiative, as it will offer not only a safe, environmentally sensible, and domestically-generated product, but it will also stimulate local employment and be an economic boost to the area.” The White Mesa Mill is currently one of the largest private employers in the county, and it is estimated that this new rare earth effort could result in an investment of hundreds of millions of dollars into the facility, which could translate into 100+ jobs in the region—one of the largest reinvestments this region has seen in decades. “In addition to the economic benefits to Utah, restoring rare earth production to the United States will greatly benefit the entire U.S. economy and manufacturing sector by providing a domestic source of clean energy materials produced to the highest global standards for environmental protection, sustainability and human rights, while also allowing for source validation and tracking from mining through final end-use applications,” added Chalmers. “With the increased demand for rare earths—up to a fivefold demand increase over the next 10 years—we will need all hands-on deck. Combined with the current resurgence in uranium, rare earths represent a truly an immense opportunity for San Juan County, the State of Utah, and the United States as a whole.”

This move by Energy Fuels comes at a time when the Biden administration has made it a priority to reestablish the rare earths industry in the US. Currently, China dominates every aspect of the REE industry from mining to the manufacturing of REE magnets. In the early 1990’s, China produced 38% of world’s REEs, the US produced 33%, Australia produced 12%, and Malaysia and India produced a combined five percent with several smaller countries making up the rest (Source: What are rare earth elements, and why are they important? | American Geosciences Institute). However, a significant shift in those percentages occurred, and by 2011 97% of the world’s REEs were produced in China. While China is expected to continue as the dominant player in the global REE industry, Energy Fuels believes it can create a low-cost, secure domestic alternative for end-users seeking diversity of supply and competition.

Headquartered in Lakewood, Colorado, Energy Fuels currently plans to ramp up to process up to at least 15,000 tons of monazite per year at its White Mesa Mill. This amount of monazite contains roughly 50% of current U.S. rare earth demand, along with significant quantities of uranium, which will be recovered for use in domestic nuclear energy production.  “Energy Fuels and our partner, Neo Performance Materials, have made significant steps toward restoring critical U.S. and European rare earth supply chains,” added Chalmers. “We are strategically seeking to increase our rare earth carbonate production in the coming years, since we first started acquiring monazite ore produced in the State of Georgia earlier this year.”

Successfully producing REEs, and physically delivering the first containers of RE Carbonate to Neo for separation, is an important achievement, not only for Energy Fuels, but also for the U.S. government and its efforts to restore critical rare earth supply chains. This is also good news for end-users of rare earth products in the U.S., EuropeJapan and elsewhere who seek alternative sources of rare earths produced in the U.S. and Europe that adhere to the highest global regulations and standards of environmental protection and sustainability as well as keeping a close eye on human rights.

Because monazite contains naturally occurring radioactive elements, including uranium, the White Mesa Mill is the ideal location to process this valuable material. The Mill will recover the uranium from the monazite, which will be used for the generation of clean nuclear energy. The Mill is also evaluating the recovery of thorium which has potential uses in advanced nuclear technologies along with medical isotopes needed for emerging targeted alpha cancer therapies. In addition, the monazite that is received from Georgia contains over 50% REEs, which means Energy Fuels can recover large quantities of REEs while generating relatively tiny amounts of waste. “We have an exceptional track record of environmental protection and regulatory compliance at the Mill. We also have a lot of experience in safely handling and working responsibly with low-level, natural radioactive elements contained in a variety of uranium ores and recycled alternate feed materials,” stated Curtis Moore, Energy Fuels’ VP of Marketing and Corporate Development. “Monazite sand contains roughly the same percentage of uranium as the ore found in mines in the Four Corners’ region. So, we know we will responsibly process it for the recovery of the raw materials needed for various clean energy and advanced technologies. The safety of our community and our employees is and will always remain paramount. We also are evaluating how we can do more for our local communities, particularly local Navajo, Ute, and other Native American communities.”

“Energy Fuels recognizes the lingering distrust in communities that witnessed and experienced the health and environmental impacts from historic Cold War uranium mining operations, which continue to impact perceptions. We are deeply committed to addressing the world’s most pressing environmental issues, while advancing toward the electrification of the world economy. We believe that unlocking the value of domestically produced monazite and the domestic production of rare earths, combined with our existing uranium business, is a significantly positive step.” Energy Fuels has and continues to be profoundly committed to responsible and modern mining and production, and all U.S. uranium and REE production is done to the highest global standards for environmental protection and human rights.

About Energy Fuels: Energy Fuels is a leading US-based uranium mining company, supplying U3O8 to major nuclear utilities. Energy Fuels also produces vanadium for certain projects, as market conditions warrant, as well as rare earth carbonate. With corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees in the United States, Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch ISR Project in Wyoming, and the Alta Mesa ISR Project in Texas. Energy Fuels’ website is www.energyfuels.com.

CAUTIONARY STATEMENTS REGARDING FORWARD LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may relate to future events or future performance of Energy Fuels. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation as to future production of uranium at the Mill; any expectation as to future production of rare earth products at the Mill or creation of a new U.S. to Europe supply chain; any expectation as to the Company’s ability to increase rare earth carbonate production; any expectations as to increased demand for rare earths; any expectation as to future production of thorium and other radioisotopes for use in emerging targeted alpha therapies; any expectation as to future revenues at the Mill; any expectation that San Juan County or Utah will realize significant economic benefits or that the Company’s rare earth initiative will create 100+ jobs; any expectation that Energy Fuels will reverse America’s reliance on imports or lessen the risk of disruption for critical minerals; any expectation that Energy Fuels will create a low-cost, secure domestic alternative for end-users seeking diversity of supply and competitionOften, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: commodity prices; processing difficulties and upsets; available supplies of monazite sands; the capital and operating costs associated with the recovery of uranium, rare earth products, thorium and other radioisotopes at the Mill; licensing, permitting and regulatory delays; litigation risks; competition from others; market factors, including future demand for and prices realized from the sale of uranium, rare earth products, and thorium or other radioisotopes produced at the Mill. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels assumes no obligation to update the information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.

Energy Fuels Establishes the San Juan County Clean Energy Foundation with Potential to Contribute Millions to Local Communities

 

 


Energy Fuels Establishes the San Juan County Clean Energy Foundation with Potential to Contribute Millions to Local Communities

 

BLANDING, UtahSept. 16, 2021 /CNW/ – At its recent open house showcasing its uranium and rare earth businesses for local and national dignitaries and industry leaders, Energy Fuels Inc. (“Energy Fuels” or the “Company”) announced the establishment of the San Juan County Clean Energy Foundation, a fund specifically designed to contribute to the communities surrounding Energy Fuels’ White Mesa Mill in Southeastern, Utah. 

          This week, Energy Fuels deposited $1 million into the Foundation and anticipates providing ongoing annual funding equal to 1% of the Mill’s future revenues, providing funding to support the local economy and local priorities. The Foundation will focus on supporting education, the environment, health/wellness, and economic advancement in the City of BlandingSan Juan County, the White Mesa Ute Community, the Navajo Nation and other area communities. 

          “The communities that surround our facility deserve to share in the benefits of the Mill’s clean energy future,” said Mark Chalmers, CEO of Energy Fuels. “Uranium, which is the fuel for carbon-free, emission-free baseload nuclear power, is one of the cleanest forms of energy in the world. The rare earth’s we are now producing are used for the manufacture of permanent magnets for electric vehicles, wind turbines and other clean energy and modern technologies, and the thorium and other radioisotopes we are evaluating for recovery from our rare earth and uranium processing streams have the potential to provide the isotopes needed for emerging targeted alpha therapy cancer-fighting therapeutics. The very heart of our business – uranium and rare-earth production and recycling – helps us play a big part in addressing global climate change, reducing air pollution, and making the world a cleaner and healthier place. We see San Juan County as becoming a critical minerals hub for the U.S., and we believe the Foundation is truly the best way to make an impact and difference in the lives of those who work alongside us as we pursue these goals.”

          Company executives met with local community members to better understand and identify how the Foundation will strategically support the local communities and how to best structure the Foundation. 

          “Energy Fuels has long been a major contributor to not only the employment base of the community but also for the well-being and prosperity of this region,” said Blanding’s Mayor Joe B. Lyman. “Over the last year, the Company has met with local community members to understand and identify needs in the area. The formation of the Foundation is a culmination of these efforts and the beginning of a long-term commitment to improve the quality of life for everyone in the San Juan County area to help us reach our full potential.” To ensure that the Foundation’s contributions are well-planned and correspond to the specific needs and aspirations of the communities, the Foundation will have a community-based Advisory Board to help it determine the best allocation for the funds.  

          “The processing of rare earths at the White Mesa Mill, in addition to processing and recycling uranium, is one of the best opportunities I have seen in my entire 40+ year career, as electric vehicles, renewable energy systems, and other clean energy and advanced technologies drive demand,” continued Mr. Chalmers. “And, the potential to also extract isotopes that can be used to fight cancer is a very important added opportunity. Investing back into the San Juan County community will give us the opportunity to help support and catalyze sustainable economic and community development, beyond good jobs and more tax revenues.” 

          With a population of a little more than 3,000 people, Blanding is the most populous city in San Juan County. Economic contributors include mineral processing, mining, agriculture, local commerce, tourism, and transportation. The community is also a gateway to nearby natural, cultural and archaeological resources. Energy Fuels’ rare earth initiative will only involve mineral processing, and it is not expected to involve any new mining in the region. 

          Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8?to major nuclear utilities. Energy Fuels also produces vanadium from certain projects, as market conditions warrant, as well as rare earth carbonate. With corporate offices in?Lakewood, Colorado, near?Denver, and all of its assets and employees in?the United States, Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in?Utah, the Nichols Ranch in-situ recovery (ISR) Project in?Wyoming, and the Alta Mesa ISR Project in?Texas. Energy Fuels is a publicly traded company on the NYSE under the trading symbol “UUUU,” and its common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is?www.energyfuels.com  

CAUTIONARY STATEMENTS REGARDING FORWARD LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may relate to future events or future performance of Energy Fuels. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation as to future production of uranium at the Mill; any expectation as to future production of rare earth products at the Mill; any expectation as to future production of thorium and other radioisotopes for use in emerging targeted alpha therapies; any expectation as to future revenues at the Mill; any expectation that San Juan County will become a critical minerals hub for the U.S.; any expectation as to any ongoing annual funding for the Foundation or the longevity of the Foundation; any expectation that the Foundation will provide the potential to contribute millions to local communities; any expectation as to the manner in which the Foundation will distribute or invest its funds; and any expectation that the Foundation’s money will help support and catalyze sustainable economic and community development, beyond good jobs and more tax revenues. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: commodity prices; processing difficulties and upsets; available supplies of monazite sands; the capital and operating costs associated with the recovery of uranium, rare earth products, thorium and other radioisotopes at the Mill; licensing, permitting and regulatory delays; litigation risks; competition from others; market factors, including future demand for and prices realized from the sale of uranium, rare earth products, and thorium or other radioisotopes produced at the Mill; and any changes that may be made to the structure, funding or term of the Foundation if the Company determines at any time that the Foundation is not achieving its objectives or to better meet its objectives. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels assumes no obligation to update the information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.

Indonesia Energy Corp (INDO) – Results for 2nd well surpass expectations

Thursday, September 16, 2021

Indonesia Energy Corp (INDO)
Results for 2nd well surpass expectations

Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. It holds two oil and gas assets through its subsidiaries in Indonesia: one producing block (the Kruh Block) and one exploration block (the Citarum Block). The Kruh Block is located to the northwest of Pendopo, Pali, South Sumatra. The Citarum Block is located to the south of Jakarta.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Indo announced that it has discovered oil in its Kruh 26 well. The discovery follows similar success at the initial Kruh 25 well and was largely expected. Drilling was done in only 18 days at a cost below initial expectations of $1.5 million. Drilling encountered a larger-than-expected pay zone implying that reserves may be higher than expected. Production for the first two wells is expected in the fourth quarter, in line with expectations.

    Drilling continues albeit with fewer wells to be drilled in 2021.  The company still plans to drill 18 wells in 2021-23 but will only do three in 2021 instead of five. The company has faced several drilling delays since it started its drilling program, mostly due to COVID issues. The most recent delay does not change our overall profile of valuation for the company, but we will be watching future …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Helius Medical Technologies (HSDT)(HSM:CA) – CMS to Scrap MCIT? Implications for Helius

Thursday, September 16, 2021

Helius Medical Technologies (HSDT)(HSM:CA)
CMS to Scrap MCIT? Implications for Helius

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Gregory Aurand, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    MCIT Concerns. The Centers for Medicare and Medicaid Services (CMS) has announced it is planning to scrap the proposed Medicare Coverage of Innovative Technology (MCIT) payment rule that would have allowed four years of Medicare coverage for breakthrough device designated technologies. While an unfortunate setback, we do not believe the potential loss of MCIT to be material to the Helius story.

    Not Quite Dead Yet.  While CMS may be looking to scrap MCIT following a 30 day comment period, the proposal was recently included in a discussion draft for the 21st Century Cures Act which is expected to come up in next year’s legislative calendar. So a form of MCIT may be revised shortly in any case …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.